Clinical trials: Vitrectomy
Diabetes
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds
As a consequence of damage to multiple organ systems throughout the course of their disease, diabetic patients suffer a number of chronic complications giving rise to increased morbidity, mortality, and health care costs specific…
- Trial name
- NCT00598871
- Testing
- Thymosin Beta 4 (Tβ4)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- ReGenTree, LLC
Diabetic Macular Edema, Vitrectomy
Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant in the study eye of vitrectomized subjects with diabetic macular edema. Subjects will be followed for 26 weeks.
- Trial name
- NCT00799227
- Testing
- Dexamethasone
- Where
- 2 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Allergan
Symptomatic Vitreomacular Adhesion
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
- Trial name
- NCT01889251
- Testing
- Ocriplasmin
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Alcon Research
Vitreoretinal Disease
Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes
The purpose of this study is to compare the treatment day change between immediate postoperative and immediate preoperative intraocular pressure (IOP) between 27-gauge and 23-gauge vitrectomy instruments.
- Trial name
- NCT02477605
- Testing
- CONSTELLATION® 27-gauge Combined Surgical Pak, CONSTELLATION® 23-gauge Combined Surgical Pak, Vitrectomy surgery
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Alcon Research
Vitrectomy
Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
This study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.
- Trial name
- NCT01319318
- Testing
- Pars Plana Vitrectomy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Allergan
Vitrectomy
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients.
- Trial name
- MIC (NCT00986362)
- Testing
- Ocriplasmin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- ThromboGenics
Vitrectomy
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)
- Trial name
- MIVI-10 (NCT01159665)
- Testing
- ocriplasmin
- Where
- Belgium
- Volunteers
- 38 people
- Sponsor
- ThromboGenics
Vitrectomy
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.
- Trial name
- NCT00412958
- Testing
- Ocriplasmin 25µg, Ocriplasmin 75µg, Ocriplasmin 125µg
- Where
- 20 sites in United States
- Volunteers
- 125 people
- Sponsor
- ThromboGenics
Vitrectomy
Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to…
- Trial name
- NCT01229410
- Testing
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
- Where
- 2 sites in United States, Czechia
- Volunteers
- 24 people
- Sponsor
- Allergan
Vitreomacular Traction, Vitreomacular Adhesion
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
- Trial name
- NCT02322229
- Testing
- Ocriplasmin 0.125 mg in a 0.1 mL volume
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Alcon Research